发布求助
文献互助 智能选刊 最新文献

European Journal of Clinical Microbiology最新文献

筛选
英文 中文
Comparative in vitro activity of RO 23-6240 (fleroxacin), a new 4-quinolone derivative. 新型4-喹诺酮类衍生物氟罗沙星RO 23-6240的体外活性比较。
European Journal of Clinical Microbiology Pub Date : 1987-08-01 DOI: 10.1007/BF02013116
K Machka, I Braveny
{"title":"Comparative in vitro activity of RO 23-6240 (fleroxacin), a new 4-quinolone derivative.","authors":"K Machka,&nbsp;I Braveny","doi":"10.1007/BF02013116","DOIUrl":"https://doi.org/10.1007/BF02013116","url":null,"abstract":"<p><p>The in vitro activity of RO 23-6240 was compared with that of norfloxacin, ofloxacin and ciprofloxacin as well as four other antimicrobial agents against 345 recent clinical isolates. The MICs of RO 23-6240 against Enterobacteriaceae and Acinetobacter anitratum was less than or equal to 0.5 mg/l. At the same concentration of the compound 90% of staphylococci were inhibited. Against Enterococcus faecalis and Pseudomonas aeruginosa RO 23-6240 proved less active, having MIC90 values of 4.0 mg/l and 8.0 mg/l, respectively. Enterobacteriaceae and staphylococci strains that were resistant to piperacillin, cefotaxime or tobramycin were susceptible to the compound. In general the activity of RO 23-6240 was comparable to those of norfloxacin and ofloxacin, but less than that of ciprofloxacin.</p>","PeriodicalId":11958,"journal":{"name":"European Journal of Clinical Microbiology","volume":"6 4","pages":"482-5"},"PeriodicalIF":0.0,"publicationDate":"1987-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02013116","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14248858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Comparative in vitro activity of the new macrolide A-56268 against anaerobic bacteria. 新型大环内酯A-56268体外抗厌氧菌活性比较。
European Journal of Clinical Microbiology Pub Date : 1987-08-01 DOI: 10.1007/BF02013121
H M Wexler, S M Finegold
{"title":"Comparative in vitro activity of the new macrolide A-56268 against anaerobic bacteria.","authors":"H M Wexler,&nbsp;S M Finegold","doi":"10.1007/BF02013121","DOIUrl":"https://doi.org/10.1007/BF02013121","url":null,"abstract":"","PeriodicalId":11958,"journal":{"name":"European Journal of Clinical Microbiology","volume":"6 4","pages":"492-4"},"PeriodicalIF":0.0,"publicationDate":"1987-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02013121","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14094056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
In vitro activity of the new quinolone RO 23-6240 (AM-833) and the new cephalosporins RO 15-8074 and RO 19-5247 (T-2525) against Mycobacterium fortuitum and Mycobacterium chelonae. 新型喹诺酮类药物RO 23-6240 (AM-833)和新型头孢菌素RO 15-8074和RO 19-5247 (T-2525)对福氏分枝杆菌和chelonae分枝杆菌的体外活性研究。
European Journal of Clinical Microbiology Pub Date : 1987-08-01 DOI: 10.1007/BF02013118
P Hohl, M Salfinger, F M Kafader
{"title":"In vitro activity of the new quinolone RO 23-6240 (AM-833) and the new cephalosporins RO 15-8074 and RO 19-5247 (T-2525) against Mycobacterium fortuitum and Mycobacterium chelonae.","authors":"P Hohl,&nbsp;M Salfinger,&nbsp;F M Kafader","doi":"10.1007/BF02013118","DOIUrl":"https://doi.org/10.1007/BF02013118","url":null,"abstract":"","PeriodicalId":11958,"journal":{"name":"European Journal of Clinical Microbiology","volume":"6 4","pages":"487-8"},"PeriodicalIF":0.0,"publicationDate":"1987-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02013118","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14248061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
In vitro activity of various new antimicrobial agents against group JK corynebacteria. 几种新型抗菌药物对JK群棒状细菌的体外活性研究。
European Journal of Clinical Microbiology Pub Date : 1987-08-01 DOI: 10.1007/BF02013120
K V Rolston, G P Bodey
{"title":"In vitro activity of various new antimicrobial agents against group JK corynebacteria.","authors":"K V Rolston,&nbsp;G P Bodey","doi":"10.1007/BF02013120","DOIUrl":"https://doi.org/10.1007/BF02013120","url":null,"abstract":"","PeriodicalId":11958,"journal":{"name":"European Journal of Clinical Microbiology","volume":"6 4","pages":"491-2"},"PeriodicalIF":0.0,"publicationDate":"1987-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02013120","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14786695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Comparative in vitro activity of the new macrolide A-56268 against mycobacteria. 新型大环内酯A-56268体外抗分枝杆菌活性比较。
European Journal of Clinical Microbiology Pub Date : 1987-08-01 DOI: 10.1007/BF02013117
O G Berlin, L S Young, S A Floyd-Reising, D A Bruckner
{"title":"Comparative in vitro activity of the new macrolide A-56268 against mycobacteria.","authors":"O G Berlin,&nbsp;L S Young,&nbsp;S A Floyd-Reising,&nbsp;D A Bruckner","doi":"10.1007/BF02013117","DOIUrl":"https://doi.org/10.1007/BF02013117","url":null,"abstract":"","PeriodicalId":11958,"journal":{"name":"European Journal of Clinical Microbiology","volume":"6 4","pages":"486-7"},"PeriodicalIF":0.0,"publicationDate":"1987-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02013117","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14094055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Atrio-ventricular block associated with Shigella flexneri infection. 与福氏志贺氏菌感染相关的房室传导阻滞。
European Journal of Clinical Microbiology Pub Date : 1987-08-01 DOI: 10.1007/BF02013129
I Ovsyshcher, L Rudnik, M Alkan, R Ilia
{"title":"Atrio-ventricular block associated with Shigella flexneri infection.","authors":"I Ovsyshcher,&nbsp;L Rudnik,&nbsp;M Alkan,&nbsp;R Ilia","doi":"10.1007/BF02013129","DOIUrl":"https://doi.org/10.1007/BF02013129","url":null,"abstract":"","PeriodicalId":11958,"journal":{"name":"European Journal of Clinical Microbiology","volume":"6 4","pages":"504"},"PeriodicalIF":0.0,"publicationDate":"1987-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02013129","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14439338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Comparative in vitro activity of cefetamet (RO 15-8074). 头孢他美(ro15 -8074)的体外活性比较。
European Journal of Clinical Microbiology Pub Date : 1987-08-01 DOI: 10.1007/BF02013123
K Machka, I Braveny
{"title":"Comparative in vitro activity of cefetamet (RO 15-8074).","authors":"K Machka,&nbsp;I Braveny","doi":"10.1007/BF02013123","DOIUrl":"https://doi.org/10.1007/BF02013123","url":null,"abstract":"","PeriodicalId":11958,"journal":{"name":"European Journal of Clinical Microbiology","volume":"6 4","pages":"496-7"},"PeriodicalIF":0.0,"publicationDate":"1987-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02013123","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14602023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Streptococcus milleri infection of a hepatopulmonary hydatid cyst. 肝肺包虫病的米勒链球菌感染。
European Journal of Clinical Microbiology Pub Date : 1987-08-01 DOI: 10.1007/BF02013097
R G Masterton, M J O'Doherty, S J Eykyn
{"title":"Streptococcus milleri infection of a hepatopulmonary hydatid cyst.","authors":"R G Masterton,&nbsp;M J O'Doherty,&nbsp;S J Eykyn","doi":"10.1007/BF02013097","DOIUrl":"https://doi.org/10.1007/BF02013097","url":null,"abstract":"<p><p>A case of hepatopulmonary hydatid disease in a Cypriot who presented with pyogenic infection with Streptococcus milleri is described. Although hydatid disease and pyogenic liver abscess are both rare in the UK, an underlying echinococcal pathology should be suspected in any patient from an area endemic for hydatid who presents with a pyogenic hepatic or hepatopulmonary abscess.</p>","PeriodicalId":11958,"journal":{"name":"European Journal of Clinical Microbiology","volume":"6 4","pages":"414-5"},"PeriodicalIF":0.0,"publicationDate":"1987-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02013097","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14786688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods. 革兰氏阴性杆状细胞β -内酰胺酶诱导及稳定抑制的临床意义。
European Journal of Clinical Microbiology Pub Date : 1987-08-01 DOI: 10.1007/BF02013107
D M Livermore
{"title":"Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods.","authors":"D M Livermore","doi":"10.1007/BF02013107","DOIUrl":"https://doi.org/10.1007/BF02013107","url":null,"abstract":"<p><p>Most strains of enterobacteria and Pseudomonas aeruginosa produce chromosomally-determined Class I beta-lactamases. When synthesized copiously these enzymes cause resistance to almost all beta-lactams, except imipenem and, sometimes, carbenicillin and tenocillin. Elevated beta-lactamase production arises transiently, via induction, in Pseudomonas aeruginosa and Enterobacter, Citrobacter, Morganella, indole-positive Proteus and Serratia spp. when these organisms are exposed to beta-lactams. Permanent high-level enzyme production arises via mutation, in the stably-derepressed mutants of these species. These mutants arise spontaneously at high frequency (10(-5) -10(-8). Most early penicillins and first-generation cephalosporins are strong inducers of Class I enzymes at sub-inhibitory concentrations, as are cefoxitin and imipenem. Consequently their MICs reflect what lability these antibiotics have to inducibly-expressed beta-lactamase. Except with imipenem this lability usually is so great that the inducible enzyme causes clinical resistance. Although most other newer cephalosporins and ureidopenicillins are labile to the Class I enzymes they induce poorly below the MIC, and their lability is not reflected in resistance unless secondary inducers (e.g. cefoxitin or imipenem) are present. Although the weak inducer activity of these agents helps to maintain their activity against the inducible cells it renders the drugs highly selective for the pre-existing stably-derepressed mutants. Many cases have been reported where stably-derepressed mutants have overrun inducible populations of bacteria in patients undergoing therapy with beta-lactamase-labile weak inducers such as ureidopenicillin and third-generation cephalosporins.</p>","PeriodicalId":11958,"journal":{"name":"European Journal of Clinical Microbiology","volume":"6 4","pages":"439-45"},"PeriodicalIF":0.0,"publicationDate":"1987-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02013107","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14439337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 119
In vitro and in vivo susceptibility of Borrelia burgdorferi. 伯氏疏螺旋体的体外和体内敏感性。
European Journal of Clinical Microbiology Pub Date : 1987-08-01 DOI: 10.1007/BF02013102
V P Mursic, B Wilske, G Schierz, M Holmburger, E Süss
{"title":"In vitro and in vivo susceptibility of Borrelia burgdorferi.","authors":"V P Mursic,&nbsp;B Wilske,&nbsp;G Schierz,&nbsp;M Holmburger,&nbsp;E Süss","doi":"10.1007/BF02013102","DOIUrl":"https://doi.org/10.1007/BF02013102","url":null,"abstract":"<p><p>The antispirochetal activity in vitro and in vivo of several antibiotics against ten isolates of Borrelia burgdorferi from human spinal fluids and skin biopsies was determined. Borrelia burgdorferi was most susceptible in vitro to erythromycin, ceftriaxone and cefotaxime (MIC90: 0.06, 0.06, 0.12 mcg/ml respectively). Less activity was observed with tetracycline, amoxycillin and lincomycin (MIC90: 0.50 mcg/ml), imipenem and augmentin (MIC90: 0.25 mcg/ml), oxacillin (MIC90: 1 mcg/ml), ciprofloxacin (MIC90: 2 mcg/ml) and ofloxacin (MIC90: 4 mcg/ml). Penicillin G, normally regarded as appropriate treatment for Lyme disease, had an MIC90 of only 4 mcg/ml. With the exception of erythromycin, activity in vitro corresponded to the activity in vivo. Erythromycin, however, was less active in vivo, and penicillin G showed poor activity both in vitro and in vivo.</p>","PeriodicalId":11958,"journal":{"name":"European Journal of Clinical Microbiology","volume":"6 4","pages":"424-6"},"PeriodicalIF":0.0,"publicationDate":"1987-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02013102","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14786691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 36
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信